Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 1215Triple Negative Breast Neoplasms 284Ovarian Neoplasms 262Carcinoma, Non-Small-Cell Lung 249Colorectal Neoplasms 190Pancreatic Neoplasms 168Stomach Neoplasms 164Neoplasm Metastasis 156Neoplasms 155Lung Neoplasms 144Prostatic Neoplasms 143Melanoma 132Carcinoma, Renal Cell 103Squamous Cell Carcinoma of Head and Neck 102Endometrial Neoplasms 99Head and Neck Neoplasms 88Colonic Neoplasms 82Urinary Bladder Neoplasms 79Uterine Cervical Neoplasms 77Esophageal Neoplasms 76Sarcoma 72Breast Neoplasms, Male 68Small Cell Lung Carcinoma 66Carcinoma, Hepatocellular 60Carcinoma, Ovarian Epithelial 58Kidney Neoplasms 47Carcinoma, Transitional Cell 41Rectal Neoplasms 35Fallopian Tube Neoplasms 34Liver Neoplasms 32

Interventions

Paclitaxel 2Carboplatin 2talazoparib 1olaparib 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Metastatic Breast Cancer × Breast × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

University of California, San Francisco

Phase 1 Terminated
23 enrolled
BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡